Vivione Biosciences Announces Clinical Pilot With The Cleveland Clinic Department Of Pathology

LITTLE ROCK, Ark.--(BUSINESS WIRE)--Vivione Biosciences Inc. (“Vivione”) (TSX:VBI), through its wholly owned subsidiary, Vivione Biosciences, LLC, is pleased to announce that it will begin a clinical pilot evaluation of its RAPID-B platform at the prestigious Cleveland Clinic Department of Pathology.

Vivione will apply its highly sensitive and quantitative RAPID-B platform technology to urinary tract infection screenings through the pilot. Early internal data from Vivione has shown that RAPID-B can be used for the initial screening of urine specimens prior to any culture requirements to determine true infection versus contamination. The RAPID-B platform has the ability to deliver test results at the time of specimen delivery, which is up to 48 hours faster than a traditional urine culture. With its ability to quickly deliver quantitative results, this technology can reduce laboratory resource needs and associated expenditures.

Help employers find you! Check out all the jobs and post your resume.

Back to news